HRMY
Harmony Biosciences Holdings, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24
Figures on this page computed 2026-11-08 12:32 UTC
Last close
34.42USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-24
12.0xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-24
53.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
18.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
40.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
0.19Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth40.3%72 of 100, above its sector
- Returns on capital53.6%91 of 100, above its sector
- Margins77.2%90 of 100, above its sector
- Price12.0x54 of 100, above its sector
- Safety0.1975 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 3 of 4- Profit on each unit of sales18.3%39.2%Behind
Higher is better here.
- Return on the capital it uses53.6%n/an/a
Higher is better here.
- Sales growth over five years40.3%18.8%Ahead
Higher is better here.
- Debt against equity0.19n/an/a
Lower is better here.
- Gross margin77.2%93.5%Behind
Higher is better here.
- Price against earnings12x4.0xBehind
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Novavax, Inc., HRMY is behind on 3 of 4 measures.
Against Novavax, Inc., HRMY is behind on 3 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-24
Profit on each unit of sales18.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
Return on the capital it uses53.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
Sales growth over five years40.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
Debt against equity0.19
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
Gross margin77.2%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD
Price against earnings12.0x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-018859
- Reported in
- USD